Xiaojing Shi1,2, Pengfei Xu3, Caiguang Cao1,2, Zhen Cheng4, Jie Tian5,6,7, Zhenhua Hu8,9. 1. CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. 2. School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. 3. Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China. 4. State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. zcheng@simm.ac.cn. 5. CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. jie.tian@ia.ac.cn. 6. School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. jie.tian@ia.ac.cn. 7. Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing, China. jie.tian@ia.ac.cn. 8. CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. zhenhua.hu@ia.ac.cn. 9. School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. zhenhua.hu@ia.ac.cn.
Abstract
PURPOSE: The surgery of glioblastoma (GBM) requires a maximal resection of the tumor when it is safe and feasible. The infiltrating growth property of the GBM makes it a challenge for neurosurgeons to identify the tumor tissue even with the assistance of the surgical microscope. This highlights the urgent requirement for imaging techniques that can differentiate tumor tissues during surgery in real time. Fluorescence image-guided surgery of GBM has been investigated using several non-specific fluorescent probes that emit light in the visible and the first near-infrared window (NIR-I, 700-900 nm), which limit the detection accuracy because of the non-specific targeting mechanism and spectral characteristics. Targeted NIR-II (1000-1700 nm) fluorescent probes for GBM are thus highly desired. The folate receptor (FR) has been reported to be upregulated in GBM, which renders it to be a promising target for specific tumor imaging. METHODS: In this study, the folic acid (FA) that can target the FR was conjugated with the clinically approved indocyanine green (ICG) dye and DOTA chelator for radiolabeling with 64Cu to achieve targeted positron emission tomography (PET) and fluorescence imaging of GBM. RESULTS: Surprisingly it was found that the resulted bioconjugate, DOTA-FA-ICG and non-radioactive natCu-DOTA-FA-ICG, were both self-assembled into nanoparticles with NIR-II emission signal. The radiolabeled DOTA-FA-ICG, 64Cu-DOTA-FA-ICG, was found to specifically accumulate in the orthotopic GBM models using in vivo PET, NIR-II, and NIR-I fluorescence imaging. The best time window of fluorescence imaging was demonstrated to be 24 h after DOTA-FA-ICG injection. NIR-II fluorescence image-guided surgery was successfully conducted in the orthotopic GBM models using DOTA-FA-ICG. All the fluorescent tissue was removed and proved to be GBM by the H&E examination. CONCLUSION: Overall, our study demonstrates that the probes, 64Cu-DOTA-FA-ICG and DOTA-FA-ICG, hold promise for preoperative PET examination and intraoperative NIR-II fluorescence image-guided surgery of GBM, respectively.
PURPOSE: The surgery of glioblastoma (GBM) requires a maximal resection of the tumor when it is safe and feasible. The infiltrating growth property of the GBM makes it a challenge for neurosurgeons to identify the tumor tissue even with the assistance of the surgical microscope. This highlights the urgent requirement for imaging techniques that can differentiate tumor tissues during surgery in real time. Fluorescence image-guided surgery of GBM has been investigated using several non-specific fluorescent probes that emit light in the visible and the first near-infrared window (NIR-I, 700-900 nm), which limit the detection accuracy because of the non-specific targeting mechanism and spectral characteristics. Targeted NIR-II (1000-1700 nm) fluorescent probes for GBM are thus highly desired. The folate receptor (FR) has been reported to be upregulated in GBM, which renders it to be a promising target for specific tumor imaging. METHODS: In this study, the folic acid (FA) that can target the FR was conjugated with the clinically approved indocyanine green (ICG) dye and DOTA chelator for radiolabeling with 64Cu to achieve targeted positron emission tomography (PET) and fluorescence imaging of GBM. RESULTS: Surprisingly it was found that the resulted bioconjugate, DOTA-FA-ICG and non-radioactive natCu-DOTA-FA-ICG, were both self-assembled into nanoparticles with NIR-II emission signal. The radiolabeled DOTA-FA-ICG, 64Cu-DOTA-FA-ICG, was found to specifically accumulate in the orthotopic GBM models using in vivo PET, NIR-II, and NIR-I fluorescence imaging. The best time window of fluorescence imaging was demonstrated to be 24 h after DOTA-FA-ICG injection. NIR-II fluorescence image-guided surgery was successfully conducted in the orthotopic GBM models using DOTA-FA-ICG. All the fluorescent tissue was removed and proved to be GBM by the H&E examination. CONCLUSION: Overall, our study demonstrates that the probes, 64Cu-DOTA-FA-ICG and DOTA-FA-ICG, hold promise for preoperative PET examination and intraoperative NIR-II fluorescence image-guided surgery of GBM, respectively.
Authors: John Y K Lee; Jayesh P Thawani; John Pierce; Ryan Zeh; Maria Martinez-Lage; Michelle Chanin; Ollin Venegas; Sarah Nims; Kim Learned; Jane Keating; Sunil Singhal Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: Stephen G Bowden; Justin A Neira; Brian J A Gill; Timothy H Ung; Zachary K Englander; George Zanazzi; Peter D Chang; Jorge Samanamud; Jack Grinband; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Peter Canoll; Randy S D'Amico; Jeffrey N Bruce Journal: Neurosurgery Date: 2018-05-01 Impact factor: 4.654
Authors: Bogdana Suchorska; Nathalie L Jansen; Jennifer Linn; Hans Kretzschmar; Hendrik Janssen; Sabina Eigenbrod; Matthias Simon; Gabriele Pöpperl; Friedrich W Kreth; Christian la Fougere; Michael Weller; Joerg C Tonn Journal: Neurology Date: 2015-01-21 Impact factor: 9.910
Authors: Sophie Hernot; Labrinus van Manen; Pieterjan Debie; Jan Sven David Mieog; Alexander Lucas Vahrmeijer Journal: Lancet Oncol Date: 2019-07 Impact factor: 41.316
Authors: Francesco Acerbi; Morgan Broggi; Karl-Michael Schebesch; Julius Höhne; Claudio Cavallo; Camilla De Laurentis; Marica Eoli; Elena Anghileri; Maura Servida; Carlo Boffano; Bianca Pollo; Marco Schiariti; Sergio Visintini; Cristina Montomoli; Lorenzo Bosio; Emanuele La Corte; Giovanni Broggi; Alexander Brawanski; Paolo Ferroli Journal: Clin Cancer Res Date: 2017-10-10 Impact factor: 12.531
Authors: Annette M Molinaro; Shawn Hervey-Jumper; Ramin A Morshed; Jacob Young; Seunggu J Han; Pranathi Chunduru; Yalan Zhang; Joanna J Phillips; Anny Shai; Marisa Lafontaine; Jason Crane; Ankush Chandra; Patrick Flanigan; Arman Jahangiri; Gino Cioffi; Quinn Ostrom; John E Anderson; Chaitra Badve; Jill Barnholtz-Sloan; Andrew E Sloan; Bradley J Erickson; Paul A Decker; Matthew L Kosel; Daniel LaChance; Jeanette Eckel-Passow; Robert Jenkins; Javier Villanueva-Meyer; Terri Rice; Margaret Wrensch; John K Wiencke; Nancy Ann Oberheim Bush; Jennie Taylor; Nicholas Butowski; Michael Prados; Jennifer Clarke; Susan Chang; Edward Chang; Manish Aghi; Philip Theodosopoulos; Michael McDermott; Mitchel S Berger Journal: JAMA Oncol Date: 2020-04-01 Impact factor: 33.006
Authors: Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777